357 related articles for article (PubMed ID: 25669980)
1. CXCR4 over-expression and survival in cancer: a system review and meta-analysis.
Zhao H; Guo L; Zhao H; Zhao J; Weng H; Zhao B
Oncotarget; 2015 Mar; 6(7):5022-40. PubMed ID: 25669980
[TBL] [Abstract][Full Text] [Related]
2. The impact of chemokine receptor CXCR4 on breast cancer prognosis: a meta-analysis.
Xu TP; Shen H; Liu LX; Shu YQ
Cancer Epidemiol; 2013 Oct; 37(5):725-31. PubMed ID: 23763828
[TBL] [Abstract][Full Text] [Related]
3. Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: A meta-analysis.
Wang F; Li S; Zhao Y; Yang K; Chen M; Niu H; Yang J; Luo Y; Tang W; Sheng M
Breast; 2016 Aug; 28():45-53. PubMed ID: 27214240
[TBL] [Abstract][Full Text] [Related]
4. The association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis.
Lv S; Yang Y; Kwon S; Han M; Zhao F; Kang H; Dai C; Wang R
Histopathology; 2014 Apr; 64(5):701-12. PubMed ID: 24422942
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of High CXCR4 Expression in Renal Cell Carcinoma: A System Review and Meta-Analysis.
Du Y; Long Q; Guan B; Mu L
Dis Markers; 2015; 2015():568980. PubMed ID: 26526157
[TBL] [Abstract][Full Text] [Related]
6. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.
Kim J; Takeuchi H; Lam ST; Turner RR; Wang HJ; Kuo C; Foshag L; Bilchik AJ; Hoon DS
J Clin Oncol; 2005 Apr; 23(12):2744-53. PubMed ID: 15837989
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 as a prognostic biomarker in gastrointestinal cancer: a meta-analysis.
Jiang Q; Sun Y; Liu X
Biomarkers; 2019 Sep; 24(6):510-516. PubMed ID: 31244335
[No Abstract] [Full Text] [Related]
8. The prognostic value of CXCR4 in ovarian cancer: a meta-analysis.
Liu CF; Liu SY; Min XY; Ji YY; Wang N; Liu D; Ma N; Li ZF; Li K
PLoS One; 2014; 9(3):e92629. PubMed ID: 24658065
[TBL] [Abstract][Full Text] [Related]
9. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression.
Jiang YP; Wu XH; Shi B; Wu WX; Yin GR
Gynecol Oncol; 2006 Oct; 103(1):226-33. PubMed ID: 16631235
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases.
Yopp AC; Shia J; Butte JM; Allen PJ; Fong Y; Jarnagin WR; DeMatteo RP; D'Angelica MI
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S339-46. PubMed ID: 21584832
[TBL] [Abstract][Full Text] [Related]
11. Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma.
Gockel I; Schimanski CC; Heinrich C; Wehler T; Frerichs K; Drescher D; von Langsdorff C; Domeyer M; Biesterfeld S; Galle PR; Junginger T; Moehler M
BMC Cancer; 2006 Dec; 6():290. PubMed ID: 17176471
[TBL] [Abstract][Full Text] [Related]
12. Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis.
Amara S; Chaar I; Khiari M; Ounissi D; Weslati M; Boughriba R; Hmida AB; Bouraoui S
Cancer Biomark; 2015; 15(6):869-79. PubMed ID: 26406413
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer.
Chen HW; Du CW; Wei XL; Khoo US; Zhang GJ
Curr Mol Med; 2013 Mar; 13(3):410-6. PubMed ID: 23331013
[TBL] [Abstract][Full Text] [Related]
14. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of CXCR4 and correlation with clinicopathological features and prognosis of non-small cell lung cancer patients: a meta-analysis.
Wang H; Xie F; Hu Z; Chen L
Genet Mol Res; 2015 Dec; 14(4):17893-903. PubMed ID: 26782435
[TBL] [Abstract][Full Text] [Related]
17. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
[TBL] [Abstract][Full Text] [Related]
18. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary.
Sekiya R; Kajiyama H; Sakai K; Umezu T; Mizuno M; Shibata K; Yamamoto E; Fujiwara S; Nagasaka T; Kikkawa F
Hum Pathol; 2012 Jun; 43(6):904-10. PubMed ID: 22169254
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma.
Hu F; Miao L; Zhao Y; Xiao YY; Xu Q
Drug Des Devel Ther; 2015; 9():3625-33. PubMed ID: 26203228
[TBL] [Abstract][Full Text] [Related]
20. The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.
Chen Q; Zhong T
Drug Des Devel Ther; 2015; 9():5115-22. PubMed ID: 26379424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
